Compare Herbalife Nutrition Ltd (HLF) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.75 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 43.8× Herbalife Nutrition Ltd's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| HLF | TAK | |
|---|---|---|
Market Cap | $1.34B | $58.74B |
Volume | 1,589,457 | 3,110,994 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $19.05 |
52-Week Low | $7.75 | $13.23 |
Typical Hold Time | 43 Days | 1 Days |
Enterprise Value | $3.18B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $12.86, up 1.62% on the day, with a bullish technical signal and a consensus analyst price target of $19.00 implying significant upside. The company reported Q2 2026 EPS of $0.51, missing expectations, but reaffirmed full-year 2026 guidance. Financials show a net income margin of 3.16% for 2025, with a low P/E of 8.22 and P/S of 0.26, suggesting potential undervaluation. Recent news includes a $250 million share repurchase authorization and a planned CEO transition effective October 31, 2026.
The outlook for HLF is cautiously optimistic, with valuation metrics and analyst sentiment supporting a bullish case, but risks include recent earnings misses, high debt levels, and ongoing leadership changes. The stock presents a value opportunity if the company can execute on its growth and margin expansion plans while managing its leverage.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
